Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th

Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th

SANTA MONICA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it will report its financial results for the third quarter and nine months ended September 30, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, November 7, 2018, at 4:30 p.m. Eastern Time.

Conference Call Details
Wednesday, November 7th @ 4:30pm Eastern Time/1:30pm Pacific Time
Toll Free: 866-575-6539
International: 323-994-2082
Conference ID: 3269781
Webcast: http://public.viavid.com/index.php?id=131719
   
Replays, Available through November 21st:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 3269781

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. NIDA, a division of the NIH, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its commercialization partner, Adapt Pharmaceuticals, now owned by Emergent BioSolutions, Inc.  For more information please visit: www.opiant.com.

CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
(617) 535-7746

Opiant logo.jpg

Source: Opiant Pharmaceuticals, Inc.